NRF2 is frequently upregulated in lung cancer as a consequence of somatic mutations in KEAP1, NFE2L2, or CUL3, and associates with increased cell proliferation and resistance to anticancer drugs. This evidence concerns the gene NFE2L2 and lung cancer.